Atlas Trials

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

Clinical trial NCT04543591 · COMPLETED

Trial details

NCT number
NCT04543591
Sponsor
Alexion Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Thrombotic Microangiopathy
Start date
2020-12-10
Primary completion
2025-09-19
Enrollment
148

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.